Cargando…
Pharmacogenomics of hepatitis C infections: personalizing therapy
It is a widely held view that drug response genes have not proved as useful in clinical practice as anticipated at the start of the genomic era. An exception is in the treatment for chronic hepatitis C virus (HCV) genotype 1 infection with pegylated interferon α and ribavirin. In 2009, four independ...
Autores principales: | Booth, David R, Ahlenstiel, Golo, George, Jacob |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580439/ https://www.ncbi.nlm.nih.gov/pubmed/23268841 http://dx.doi.org/10.1186/gm400 |
Ejemplares similares
-
The Role of Micronutrients in the Infection and Subsequent Response to Hepatitis C Virus
por: Gupta, Sunil, et al.
Publicado: (2019) -
The Natural Killer Cell Response to HCV Infection
por: Ahlenstiel, Golo
Publicado: (2013) -
Pharmacogenomics of chronic hepatitis C therapy with genome-wide association studies
por: Wang, Chun-Hsiang, et al.
Publicado: (2010) -
Immunomodulation of the Natural Killer Cell Phenotype and Response during HCV Infection
por: Njiomegnie, Gaitan Fabrice, et al.
Publicado: (2020) -
Clinical utility of pharmacogenomics in the management of hepatitis C
por: Trinks, Julieta, et al.
Publicado: (2014)